These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34283065)

  • 41. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Kis B; El-Haddad G; Sheth RA; Parikh NS; Ganguli S; Shyn PB; Choi J; Brown KT
    Cancer Control; 2017; 24(3):1073274817729244. PubMed ID: 28975829
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of combined therapy radiofrequency ablation/transarterial chemoembolization versus transarterial chemoembolization/radiofrequency ablation on management of hepatocellular carcinoma.
    El Dorry AK; Shaker MK; El-Fouly NF; Hussien A; El-Folly RF; El Fouly AH; Abd El Tawab K
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(12):1573-1577. PubMed ID: 32796363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma.
    Woodhead G; Lee S; Struycken L; Goldberg D; Hannallah J; Young S
    Life (Basel); 2024 Feb; 14(2):. PubMed ID: 38398726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early Stage Hepatocellular Carcinomas Not Feasible for Ultrasound-Guided Radiofrequency Ablation: Comparison of Transarterial Chemoembolization Alone and Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation.
    Hyun D; Cho SK; Shin SW; Park KB; Park HS; Choo SW; Do YS; Choo IW; Lee MW; Rhim H; Lim HK
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):417-25. PubMed ID: 26246215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.
    Poon RT; Fan ST; Tsang FH; Wong J
    Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Locoregional Approaches in Cholangiocarcinoma Treatment.
    Hare AE; Makary MS
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study.
    Yan L; Ren Y; Qian K; Kan X; Zhang H; Chen L; Liang B; Zheng C
    BMC Gastroenterol; 2021 Apr; 21(1):182. PubMed ID: 33879085
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Poor Prognosis of Advanced Cholangiocarcinoma: Real-World Data from a Tertiary Referral Center.
    Koch C; Franzke C; Bechstein WO; Schnitzbauer AA; Filmann N; Vogl T; Gruber-Rouh T; Zeuzem S; Waidmann O; Trojan J
    Digestion; 2020; 101(4):458-465. PubMed ID: 31129660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival.
    Lee DH; Lee JM; Kim PN; Jang YJ; Kang TW; Rhim H; Seo JW; Lee YJ
    Eur Radiol; 2019 Sep; 29(9):5052-5062. PubMed ID: 30770968
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update on Locoregional Therapies for Cholangiocellular Carcinoma.
    Morawitz J; Bruckmann NM; Jannusch K; Kirchner J; Antoch G; Loosen S; Luedde T; Roderburg C; Minko P
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190295
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
    J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonsurgical Approaches to Treat Biliary Tract and Liver Tumors.
    Green BL; House MG
    Surg Oncol Clin N Am; 2019 Oct; 28(4):573-586. PubMed ID: 31472906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation.
    Wang X; Liang H; Lu Z
    Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044
    [No Abstract]   [Full Text] [Related]  

  • 55. A review of the clinical diagnosis and therapy of cholangiocarcinoma.
    Yao D; Kunam VK; Li X
    J Int Med Res; 2014 Feb; 42(1):3-16. PubMed ID: 24366497
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy.
    Mauro E; Ferrer-Fàbrega J; Sauri T; Soler A; Cobo A; Burrel M; Iserte G; Forner A
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma.
    Gera S; Ettel M; Acosta-Gonzalez G; Xu R
    World J Hepatol; 2017 Feb; 9(6):300-309. PubMed ID: 28293379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radiation therapy for liver tumors: ready for inclusion in guidelines?
    Tanguturi SK; Wo JY; Zhu AX; Dawson LA; Hong TS
    Oncologist; 2014 Aug; 19(8):868-79. PubMed ID: 25001265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression.
    Cao S; Zou Y; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J
    Int J Hyperthermia; 2022; 39(1):1-7. PubMed ID: 34937501
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.
    Wakizaka K; Yokoo H; Kamiyama T; Ohira M; Kato K; Fujii Y; Sugiyama K; Okada N; Ohata T; Nagatsu A; Shimada S; Orimo T; Kamachi H; Taketomi A
    J Gastroenterol Hepatol; 2019 Jun; 34(6):1074-1080. PubMed ID: 30462849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.